Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion

Lung Cancer（2023）

引用 1|浏览12

暂无评分

摘要

•Majority of ALK-positive patients (53.6%) were PD-L1 expression TPS < 1%.•PD-L1 expression could not predict response rate of patients treated with front-line alectinib.•PD-L1 expression did not affect the survival of patients treated with front-line alectinib.

查看译文

关键词

ALK fusion,Lung cancer,PD-L1 expression,Alectinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要